A Phase IIa Clinical Study to Evaluate KAND567 against Cardiovascular Inflammation Associated with Myocardial Infarction in Patients Suffering from Myocardial Infarction
Phase of Trial: Phase II
Latest Information Update: 03 Sep 2019
Price : $35 *
At a glance
- Drugs KAND-567 (Primary)
- Indications Cardiovascular disorders; Inflammation; Myocardial infarction
- Focus Therapeutic Use
- Sponsors Kancera
- 03 Sep 2019 According to an Kancera media release, the company plans to enter Phase II for myocardial infarction in the first half of 2020.
- 06 Mar 2019 According to a Kancera media release, results from this study is expected in the second half of 2020.
- 09 Feb 2019 According to a Kancera media release, the company plans to start this trial in the second half of 2019.